

(Under Corporate Insolvency Resolution Process)Date: 27th November 2017

To

Shri Jayanta Jash / Shri P.K. Nagpal
Corporation Finance Department
Securities and Exchange Board of India
Plot No.C4-A,'G' Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400051**Copy to:****National Stock Exchange of India**
Exchange Plaza, Bandra Kurla Complex ,
Bandra (East)
Mumbai 400 051**Bombay Stock Exchange Limited**Pheroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 023
Dear Sirs,**Sub: Quarterly financial results for period ended 30th June 2017 and 30th September 2017**


As per regulation 33 (3) (a) of the SEBI (LODR), 2015, "the listed entity shall submit quarterly and year-to-date standalone financial results to the stock exchange within forty-five days of end of each quarter, other than the last quarter".

Further, as per regulation 33 (2) (b) "the financial results submitted to the stock exchange shall be signed by the chairperson or managing director, or a whole time director or in the absence of all of them; it shall be signed by any other director of the listed entity who is duly authorized by the board of directors to sign the financial results".

It may be noted that the company has not been able to publish financial statements ending June 2017 and September 2017 on time due to the following reasons:

1. The auditors delayed certifying quarterly financial results by due dates (i.e) 15/09/2017 for first quarter results and 15/12/2017 for the second quarter of FY 2017-18.
2. Vide NCLT's order dated 17th August 2017, the National Company Law Tribunal has ordered the commencement of Corporate Insolvency Resolution Process for Orchid Pharma Ltd. under the provisions of Insolvency and Bankruptcy Code 2016 ("Code") and enabling regulations. As a result of the order and under provisions of the Code, the powers of the Board of Directors stand suspended, and such powers vest in the hands of the RP. As the powers of the Board currently stand suspended, any of the existing Board of Directors would not be authorised to approve the financial results.

It may further be noted that Mr. Sripatham Venkatasubramanian Ramkumar IP Registration no. IBBI/IPA-001/IP-P00015/2016-17/10039 has been appointed as the Resolution Professional ("RP") of Orchid Pharma Ltd Vide NCLT's order dated 27th October 2017.



The financial results for the quarter ended 30th June 2017 and 30th September 2017 relate to a period before October 27, 2017 and Mr. Sripatham Venkatasubramanian Ramkumar has not had the opportunity to understand and review the books of account of this period.

The Corporate Insolvency Resolution Process is a process involving a time period of six months and is expected to be completed in March 2017.

Hence we submit that the Company be allowed an extension of time, as a one time approval, until 31/03/2018 for compliance with the regulations 33 (3) (a) and 33 (2) (b) of the SEBI (LODR), 2015.

Look forward to your support on this matter.

Kindly acknowledge receipt.

Thanking You,

Yours truly,

For Orchid Pharma Limited


Sripatham Venkatasubramanian Ramkumar

IP Registration no. IBBI/IPA-001/IP-P00015/2016-17/10039

Resolution Professional

Orchid Pharma Limited

(a company under corporate insolvency resolution process by NCLT order dated 17 August, 2017)